COMMUNIQUÉS West-GlobeNewswire

Satellos Receives FDA Fast Track Designation for SAT-3247 for the Treatment of Duchenne Muscular Dystrophy
29/06/2026
SAT-3247 has now received FDA Fast Track, Orphan Drug and Rare Pediatric Disease designations for Duchenne muscular dystrophy (“Duchenne” or “DMD”) Fast Track is designed to expedite the development/review of new drugs [...]
Agios to Host Second Quarter 2026 Financial Results Conference Call and Webcast on July 30 at 8:00 a.m. ET
29/06/2026
CAMBRIDGE, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, [...]
Sagimet Biosciences Joins the Russell 2000® and Russell 3000® Indexes
29/06/2026
SAN MATEO, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic [...]
Relmada Therapeutics Joins Russell 2000® and Russell 3000® Indexes
29/06/2026
CORAL GABLES, Fla., June 29, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central [...]
George Medicines appoints Brendan Walsh as Senior Vice President of Supply Chain & Technical Operations
29/06/2026
Brendan Walsh brings more than 20 years of operational leadership to support George Medicines’ global commercial expansion of GMRx2 London, UK, Boston, MA, 29 June 2026 – George Medicines, a late-stage biopharmaceutical [...]
Zelluna ASA: Mandatory notification of trade – Return of lent shares following Private Placement
29/06/2026
Oslo, 29 June 2026 : Reference is made to the stock exchange announcement by Zelluna ASA (the "Company") on 18 June 2026 regarding completion of a private placement of 3,143,958 new shares at a subscription price of NOK [...]
Aplagon Appoints Carl Lindgren as Board Chair to Guide Later Stage Clinical and Corporate Development
29/06/2026
Veteran life sciences executive brings over 30 years of strategic and commercial leadership as Aplagon advances through Phase 2 development in multiple thrombosis-inflammatory diseases HELSINKI, June 29, 2026 (GLOBE [...]
Resalis Announces Initiation of Phase 1b Clinical Study Evaluating RES-010 as Treatment to Address Unmet Needs in Obesity
29/06/2026
Torino, Italy, June 29, 2026 – Resalis Therapeutics today announced the dosing of the first participant in a Phase 1b clinical study of its lead candidate, RES-010, a novel antisense oligonucleotide targeting microRNA- [...]
ITM, Helmholtz Munich and the University of Münster Announce Updated Preliminary Phase 1 Data with ITM-31 in Glioblastoma Patients
29/06/2026
Patient enrollment has been completed; all enrolled patients remain alive Data presented at the Nuclear Medicine and Neuro-Oncology (NMN) Society Annual Symposium Garching/Munich and Münster, Germany - June 29, 2026 - [...]
Zelluna ASA: New share capital registered
29/06/2026
Oslo, Norway, 29 June 2026: Reference is made to the stock exchange announcement published by Zelluna ASA (the “ Company ”) on 18 June 2026 regarding a successfully placed private placement (the “ Private Placement ”) [...]
Zambon and Amneal Announce Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations
29/06/2026
Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa Hopledo® is already [...]
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
29/06/2026
COPENHAGEN, Denmark, June 29, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on June 2, 2026, under which the Company will repurchase shares for an amount up to [...]
Zelluna ASA activates The Royal Marsden as second clinical site for ZIMA-101, expanding clinical execution capabilities
29/06/2026
The Royal Marsden NHS Foundation Trust activated as the second clinical site in the ZIMA-101 Phase 1 trial Patient identification, pre-screening and screening activities ongoing at first activated site Company remains [...]
Roche announces the launch of AXELIOS 1, a transformative next-generation sequencing platform
29/06/2026
AXELIOS 1 delivers a unique combination of accuracy, speed, scalability and cost efficiency, giving laboratories of all sizes the freedom to customise their workflows and explore a wider array of applications. Powered [...]
AB Science reports completion of the step 3 of phase 1, evaluating the combination of AB8939 with venetoclax for the treatment of refractory or relapsed AML
29/06/2026
PRESS RELEASE AB SCIENCE REPORTS COMPLETION OF THE STEP 3 OF PHASE 1, EVALUATING THE COMBINATION OF AB8939 WITH VENETOCLAX FOR THE TREATMENT OF REFRACTORY OR RELAPSED ACUTE MYELOID LEUKEMIA THE COMBINATION OF AB8939 [...]
AB Science annonce l’achèvement de l’étape 3 de la phase 1, évaluant la combinaison d’AB8939 et du vénétoclax dans le traitement de la LMA réfractaire ou en rechute
29/06/2026
COMMUNIQUÉ DE PRESSE AB SCIENCE ANNONCE L’ACHÈVEMENT DE L’ÉTAPE 3 DE LA PHASE 1, ÉVALUANT LA COMBINAISON D’AB8939 ET DU VÉNÉTOCLAX DANS LE TRAITEMENT DE LA LEUCÉMIE MYÉLOÏDE AIGUË RÉFRACTAIRE OU EN RECHUTE LA [...]
Bavarian Nordic Receives Health Canada Approval for Chikungunya Vaccine
29/06/2026
COPENHAGEN, Denmark, June 29, 2026 – Bavarian Nordic A/S (OMX: BAVA) today announced that Health Canada has approved VIMKUNYA ® (recombinant, adsorbed) for immunization to prevent disease caused by chikungunya virus [...]
Ipsen to acquire Kartos Therapeutics, expanding hemato-oncology late-stage pipeline
29/06/2026
Acquisition adds navtemadlin, a late-stage rare blood cancer asset in Phase III. This hemato-oncology program in myelofibrosis expands Ipsen’s growing Oncology portfolio Navtemadlin, an oral MDM2 inhibitor, has the [...]
Ipsen acquiert Kartos Therapeutics et élargit son portefeuille d’hémato-oncologie à un stade avancé de développement
29/06/2026
Cette acquisition ajoute le navtemadlin, un candidat médicament de stade avancé contre un cancer rare du sang, actuellement en phase III de développement clinique. Ce programme d'hémato-oncologie, ciblant la [...]

Pages